United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032

The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032. The CAGR for the market from 2024 to 2032 is 14.83%. The analyst states that it amounted to US$ 1.06 Billion in 2023.

Liquid biopsy is prevalent in healthcare. It is non-invasive and detects biomarkers in blood or urine. This innovative diagnostic approach gives a much less worrying alternative to traditional tissue biopsies. It is mainly used for cancer detection and tracking. Its versatility extends past oncology, with programs in prenatal testing, infectious illnesses, and organ transplant monitoring. Liquid biopsy revolutionizes the care of patients and provides well-timed and personalized remedy strategies. This is because of ongoing improvements in technology and research.

United States Liquid Biopsy Growth Drivers

Growing Cases of Cancer

Cancer is a global pandemic. The NIH expected that in 2023, about 2.0 million people could be identified with cancer in the United States. An assessed 297,790 women and 2,800 men can be analyzed with breast cancer, which makes it the most standard cancer prognosis. Prostate cancer is the leading cancer analysis amongst men and the second most common analysis, with 288,300 anticipated instances. Lung and bronchus cancer is the third most typical cancer diagnosis, with an expected 238,340 new cases. The high incidence is propelling the United States liquid biopsy market. Evaluating cancer-related alerts using biological fluids (liquid biopsy) has generated substantial interest in the past decade. Liquid biopsies can discover a vast range of biomolecular components and feature the capability to indicate ailment status.

Increasing acceptance of Non-invasive Techniques

The rising field of liquid biopsy is at the forefront of novel diagnostic techniques for cancer and different diseases. Liquid biopsy facilitates a minimally invasive molecular definition of cancer for diagnosis, patient level to treatment, and longitudinal monitoring. Strategies encompass detecting and monitoring circulating tumor cells, cellular-free DNA, and extracellular vesicles. The NIH article observed that in the United States, in 2017, 9.8 million inpatient principal operating room methods were analyzed, of which 11.1% had been minimally invasive and 2.5% have been robot-assisted, compared with 9.6 million inpatient operating room techniques (11.2% minimally invasive and 2.9% robot-assisted) in 2018. There were 10.6, 10.6, and 10.7 million ambulatory procedures in 2016, 2017, and 2018, respectively. Ambulatory MIS processes grew, representing 16.9%, 17.4%, and 18%, respectively. This upward thrust is anticipated to add to the growth of the United States liquid biopsy market.

Emphasis on Companion Diagnostics

Companion diagnostics are in-vitro methods that offer facts about the suitability and effectiveness of a selected healing drug for an affected person before its administration. Therefore, they permit the stratification of affected person populations. Their multiplied utilization is propelling the United States liquid biopsy market. In January 2023, the FDA granted companion diagnostic designation to FoundationOne Liquid CDx to help in figuring out ROS1-superb non-small mobile lung cancer (NSCLC) or NTRK fusion-positive solid malignancies that may be handled with entrectinib (Rozlytrek). FoundationOne Liquid CDx is a next-generation sequencing-based in vitro diagnostic that analyzes 324 genes through circulating cell-free DNA by targeting throughput hybridization-based plasma derived from anti-coagulated peripheral whole blood in a population with advanced disorders.

Progress in Technology

Advancements like next-generation sequencing (NGS) drive liquid biopsy evolution. This permits precise evaluation of circulating tumor cells (CTCs) and cell-free DNA (cfDNA). These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market. Healthcare companies leverage NGS to benefit from deep insights into tumor biology and genetic mutations. This guides personalized remedies and improves results. In November 2023, Illumina Inc. introduced TruSight™ Oncology 500 ctDNA v2, expanding noninvasive complete genomic profiling (CGP) of circulating tumor DNA (ctDNA) for cases where tissue testing is unavailable or supplements tissue-based assays.

Breast Cancer could emerge as a notable focus within the Market

Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market. The demand pushes this for less-invasive early detection and monitoring diagnostic strategies. Approximately 13% of American women are projected to develop invasive breast cancer at some stage in their lifetime. An estimated 297,790 new instances of invasive breast cancer and 55,720 cases of DCIS are predicted among U.S. women in 2023. Liquid biopsies provide a minimally invasive technique for acquiring essential diagnostic information. This is highly beneficial for people affected by breast cancer.

United States Liquid Biopsy Company News

Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, and Quest Diagnostic Inc. are the leading businesses in the United States liquid biopsy market.

• In October 2023 - The FDA approved Foundation Medicine's FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for Pfizer’s BRAFTOVI® and MEKTOVI® to detect BRAF V600E mutation in metastatic non-small cell lung cancer. ClearNote Health™'s Avantect™ Pancreatic Cancer Test received a new CPT code, 0410U, facilitating reimbursement, with CMS's proposed reimbursement rate of US$ 1,160, effective January 1, 2024.
• In October 2023 - Researchers from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry secured a US$ 4.6 Million grant from the National Cancer Institute. Over five years, they will enhance liquid biopsy technologies to detect lung cancer early, addressing its status as the primary cause of cancer-related deaths in American men and women.
• In September 2023 - Exact Sciences intends to utilize its impending purchase of Resolution Bioscience to enter the next-generation sequencing-based liquid biopsy market, offering tests that complement its existing tissue-based test offerings.
• In April 2023 - Quest Diagnostics announced its agreement to acquire Haystack Oncology, a startup specializing in early-stage liquid biopsy testing for detecting residual or recurring cancer, for up to US$ 450 Million.
• In April 2023 - QIAGEN introduced the QIAseq Targeted cfDNA Ultra Panels for cancer and disease research, expediting the conversion of cfDNA liquid-biopsy samples to NGS-ready libraries in under eight hours. This addition to the QIAseq Targeted DNA product line will be showcased at QIAGEN's offerings during the 2023 American Association for Cancer Research (AACR) annual meeting in Orlando, Florida, from April 14 to 19, 2023.

Cancer Types - Market breakup in 6 viewpoints:

1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Liver Cancer
6. Other Cancer

Products - Market breakup in 3 viewpoints:

1. Kits & Reagents
2. Platforms & Instruments
3. Services

Application - Market breakup in 3 viewpoints:

1. Early Diagnosis
2. Patient Monitoring
3. Recurrence Monitoring

Biomarkers - Market breakup in 3 viewpoints:

1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Extracellular Vesicles (EVs)

Sample Types - Market breakup in 3 viewpoints:

1. Blood
2. Urine
3. Others

End-Users - Market breakup in 2 viewpoints:

1. Hospitals & Laboratories
2. Governments & Academic Research Centers

All the key players have been covered from 3 viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Thermo Fisher Scientific Inc.
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc.
4. Biocept, Inc.
5. Biocartis
6. Myriad Genetics, Inc.
7. Exact Sciences (Genomic Health)
8. NeoGenomics Laboratories
9. Quest Diagnostic Inc.